Brought to you by 
Hybrid BioSystems, Myotec merge to form PsiOxus
13 Dec 2011
Executive Summary
Imperial College London spin-out Myotec Therapeutics Ltd. (focused on muscle-wasting diseases) has merged with oncolytic virus treatment company Hybrid BioSystems Ltd. to form PsiOxus Therapeutics Ltd.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hybrid BioSystems, Myotec merge to form PsiOxus
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice